Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that severe forms of alopecia areata may be associated with poor treatment response, particularly in cases with extensive hair loss, juvenile onset, or nail changes.

This study reported that in Hispanic/Latinx patients with alopecia areata, rheumatoid arthritis was a common autoimmune comorbidity, and gastroesophageal reflux disease was notably more prevalent than in other populations with alopecia areata.

This systematic review reported that alopecia areata significantly impacts quality of life due to its psychological burdens, such as anxiety and depression, while emphasizing the need for increased awareness and support for affected individuals.

In this study, 5% minoxidil significantly improved outcomes for children and adults with patchy alopecia areata compared to placebo, with moderate quality evidence and no severe adverse events reported, though more research is needed to address remaining uncertainties.

In this case report, secukinumab therapy for spondyloarthritis was associated with the development of alopecia areata in a 46-year-old woman, which improved after discontinuing the medication.

In this clinical study, researchers reported that both sodium valproate-loaded nanospanlastics and topical corticosteroids showed comparable modest efficacy in treating patchy alopecia areata, recommending further investigation into sodium valproate's role combined with other therapies.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

This research focuses on alopecia areata, highlighting the psychological impact, especially of its variant alopecia areata incognita, and provides diagnostic and treatment tips, but does not report specific results.

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

This study found that treating patchy alopecia areata with fractional CO2 laser and topical triamcinolone acetonide was more effective and safer than intralesional triamcinolone, despite higher initial discomfort, as it resulted in greater patient satisfaction and fewer adverse effects like skin atrophy.

This article discusses the characteristics of alopecia areata, including its reversible hair loss pattern and uncertain causes, but reports no new clinical findings.

This source reports that platelet-rich plasma may be as effective as intralesional corticosteroids for treating patchy alopecia areata, with potential for earlier and more sustained results, while promising in vitro and animal studies on stem cells highlight the need for more clinical research.

This study observed that recurrent alopecia areata patients with salmon patches on the nape often had severe disease, particularly alopecia areata ophiasis, which was more common in females.

This study suggests that young females may experience a rare coexistence of Frontal Fibrosing Alopecia and ophiasis pattern Alopecia Areata, possibly sharing a common underlying pathophysiology.

This study found that CRP levels were elevated in alopecia areata patients, with an inverse linear association between serum vitamin D and CRP levels specifically noted in ophiasis AA.

This study observed a high prevalence of severe markers among pediatric alopecia areata patients, identifying AA subtotalis as more frequent, with nail changes and various hair markers suggesting progression to severe forms.

The paper concludes that the patchiness of alopecia areata is likely due to when the immune attack happens in the hair growth cycle.

This report describes a rare case of alopecia areata coexisting with primary scarring alopecia, diagnosed through detailed trichoscopic investigation, highlighting the importance of comprehensive examination for accurate diagnosis.

This Cochrane Review protocol aims to evaluate the effectiveness and safety of various treatments for alopecia areata through a network meta-analysis, but no specific study findings are reported yet.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This review discusses updated treatment guidelines for alopecia areata in Japan, highlighting new options like corticosteroid pulse therapy, but reports no new clinical results.

This article highlights differences in childhood alopecia areata compared to adult cases but reports no new clinical findings.

In this study, researchers evaluated factors influencing alopecia areata recurrence and identified male gender and a family history of the condition as independent predictors for disease recurrence among the 100 patients analyzed.

In this study, late-onset alopecia areata in Israeli patients was predominantly observed in females with mild disease, showing a high rate of complete hair regrowth but frequent relapses.

This literature review reports that treatments for alopecia areata, including topical and intralesional corticosteroids, provide varied responses, and emphasizes the importance of supporting patients emotionally, given the limited and promising evidence of effectiveness for other treatments.

In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

This study developed a simplified multidimensional assessment scale for alopecia areata severity and systemic treatment initiation among Chinese patients, achieving expert consensus on relevant clinical indicators and conditions.

This review updated the evidence on various treatments for alopecia areata, finding that minoxidil and high potency corticosteroids showed significant results in patchy AA, but the overall evidence quality was low.